Citation Impact
Citing Papers
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Engineered antibody Fc variants with enhanced effector function
2006
Membrane-tethered mucin-like polypeptides sterically inhibit binding and slow fusion kinetics of influenza A virus
2020 StandoutNobel
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Bispecific antibodies for cancer therapy
2009
Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity
2006
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Complement and cellular cytotoxicity in antibody therapy of cancer
2008
The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
2003
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
2005
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)
1991
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
2019 StandoutNatureNobel
Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
2005 Standout
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
2008
Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor
2007
The metabolic syndrome
2010 Standout
Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors.
1997
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Treatment of Non-Hodgkin's Lymphoma
1993
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
CCR4 as a novel molecular target for immunotherapy of cancer
2006
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
Non‐endocrine late complications of bone marrow transplantation in childhood: part II
2002
Fcγ receptors as regulators of immune responses
2007 Standout
Follicular B helper T cells in antibody responses and autoimmunity
2005
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen.
1992
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
2013
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
2015
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
2013 StandoutNobel
The Carbohydrate at FcγRIIIa Asn-162
2005
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
2013
Autologous bone marrow transplantation in adults with non‐Hodgkin's lymphoma: A southwest oncology group study
1994
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
1994
Immunity, Inflammation, and Cancer
2010 Standout
Follicular lymphoma international prognostic index
2006
One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome.
1993
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
2002
Activation, coactivation, and costimulation of resting human natural killer cells
2006
Hematopoietic Stem-Cell Transplantation
2006 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Prospects for the use of NK cells in immunotherapy of human cancer
2007
Activating and inhibitory FcγRs in autoimmune disorders
2006
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Complications of Endoscopic Biliary Sphincterotomy
1996 Standout
Primary brain tumours in adults
2012 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Glycocalyx Engineering with a Recycling Glycopolymer that Increases Cell Survival In Vivo
2015 StandoutNobel
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma
2005
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4
2002
Role of high-dose chemotherapy and autologous bone marrow transplantation in the treatment of lymphoma
1991
High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.
1993
The antiinflammatory activity of IgG: the intravenous IgG paradox
2007
Antibodies, Fc receptors and cancer
2007
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer
1990
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
Cancer of the Ovary
2004 Standout
Fcγ Receptors: Old Friends and New Family Members
2006
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
1994
Primary lymphoma of the central nervous system: just DLBCL or not?
2008
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Primary CNS Lymphoma in Immunocompetent Patients
2009
Autologous hematopoietic stem cell transplantation in intermediate and high grade Non-Hodgkin's lymphoma: A review
1993
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
2012
Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype
2004
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
2007
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
2003
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients
2003
Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges
2005
Immune complex–mediated antigen presentation induces tumor immunity
2002
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
2010
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
2006
A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
2008
FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
2007
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
1988
Immune complex–mediated antigen presentation induces tumor immunity
2002
Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
1994
Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study
2000
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
2000
Inhibitors of the anaplastic lymphoma kinase
2012
The Risk of Determining Risk with Multivariable Models
1993 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy
2004
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Live-Cell Labeling of Specific Protein Glycoforms by Proximity-Enhanced Bioorthogonal Ligation
2015 StandoutNobel
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
2007
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Human natural killer cells
2008
In vivo hematopoietic stem cell modification by mRNA delivery
2023 StandoutScienceNobel
Effects of insulin resistance on endothelial progenitor cells and vascular repair
2009
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Tolerogenic Dendritic Cells
2003 StandoutNobel
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
2005
Immune complex–mediated antigen presentation induces tumor immunity
2002
A controlled trial of recombinant human granulocyte-macrophage colony- stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma
1992
Immune Therapy for Cancer
2008
The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]
1995
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy
2006
Parma international protocol: pilot study of DHAP followed by involved- field radiotherapy and BEAC with autologous bone marrow transplantation
1991
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Philippe Colombat being referenced
Autologous stem cell transplantation for anaplastic large‐cell lymphomas: results of a prospective trial
2000
The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas.
1990
Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission
1989
A uniform activated B-cell–like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
2005
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT
1999
Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy
2000
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
2001
High-Dose Therapy and Autologous Bone Marrow Transplantation in First Complete or Partial Remission for Poor Prognosis Hodgkin's Disease
1996
Haemopoiesis of transplanted patients with autologous marrows assessed by long‐term marrow culture
1994
Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support
2004
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
2002
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
2004
Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage 111-IV patients
1997
Association between the SDF1‐3′A allele and high levels of CD34+ progenitor cells mobilized into peripheral blood in humans
2001
High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
1987
Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS
2012
High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin’s Lymphoma Responding to Front-Line Therapy
2003
Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France.
1997
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease.
1998
Treatment of poor prognosis Burkitt's lymphoma in adults with the Société Française d'Oncologie pdiatrique LMB protocol—A study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC)
1992